Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.69
Change (%) Stock is Up 0.05 (3.05%)
Volume2,071,591
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
10/14/14Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014Printer Friendly Version
09/29/14Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced MelanomaPrinter Friendly Version
09/17/14Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 CongressPrinter Friendly Version
09/08/14Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9Printer Friendly Version
Upcoming EventsMore >>
Q3 2014 Exelixis, Inc. Financial Results Conference Call
Tuesday, November 4, 2014 2:00 p.m. PT
Add to Calendar Add Q3 2014 Exelixis, Inc. Financial Results Conference Call to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.